First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness

Siegel, 2020, Cancer statistics, 2020, CA Cancer J Clin, 70, 7, 10.3322/caac.21590 Torre, 2016, Lung cancer statistics, Adv Exp Med Biol, 893, 1, 10.1007/978-3-319-24223-1_1 Miller, 2019, Cancer treatment and survivorship statistics, 2019, CA Cancer J Clin, 69, 363, 10.3322/caac.21565 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, New Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Vokes, 2018, Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases, Ann Oncol, 29, 959, 10.1093/annonc/mdy041 Wu, 2019, Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial, J Thorac Oncol, 14, 867, 10.1016/j.jtho.2019.01.006 Hellmann, 2019, Nivolumab plus ipilimumab in advanced non-small-cell lung cancer, New Engl J Med, 381, 2020, 10.1056/NEJMoa1910231 Sezer, 2021, Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial, Lancet, 397, 592, 10.1016/S0140-6736(21)00228-2 2021 Hoyle, 2011, Improved curve fits to summary survival data: application to economic evaluation of health technologies, BMC Med Res Methodol, 11, 139, 10.1186/1471-2288-11-139 Huang, 2017, Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States, J Med Econ, 20, 140 2021 Handorf, 2012, Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung, J Oncol Pract, 8, 267, 10.1200/JOP.2011.000502 Wu, 2017, RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources, Oncotarget, 8, 71164, 10.18632/oncotarget.17029 Billingham, 2002, Simultaneous analysis of quality of life and survival data, Stat Meth Med Res, 11, 25, 10.1191/0962280202sm269ra Hu, 2018, First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: a cost-effectiveness analysis from the UK health care perspective, Lung Cancer, 123, 166, 10.1016/j.lungcan.2018.07.012 Chouaid, 2013, Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting, J Thorac Oncol, 8, 997, 10.1097/JTO.0b013e318299243b Shrank, 2019, Waste in the US health care system: estimated costs and potential for savings, JAMA, 322, 1501, 10.1001/jama.2019.13978 Weng, 2020, Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels, Oncol Res, 28, 117, 10.3727/096504019X15707883083132 Hu, 2020, Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer, Front Oncol, 10, 1649, 10.3389/fonc.2020.01649 Verma, 2018, A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors, J Immunother Cancer, 6, 128, 10.1186/s40425-018-0442-7 Lee, 2019, Institute for Clinical and Economic Review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis, J Dermatol Treat, 30, 772, 10.1080/09546634.2019.1573307 Woods, 2016, Country-level cost-effectiveness thresholds: initial estimates and the need for further research, Value Health, 19, 929, 10.1016/j.jval.2016.02.017